Intrastriatal transplantation of adenovirus-generated induced pluripotent stem cells for treating neuropathological and functional deficits in a rodent model of Huntington's disease

Stem Cells Translational Medicine

Volumn 3, Issue 5, 2014, Pages 620-631

  Fink, Kyle D ^a,b,c,d   Crane, Andrew T ^a   Lévêque, Xavier ^a,b,e   Dues, Dylan J ^a   Huffman, Lucas D ^a   Moore, Allison C ^a   Story, Darren T ^a   DeJonge, Rachel E ^a   Antcliff, Aaron ^a   Starski, Phillip A ^a   Lu, Ming ^a,e   Lescaudron, Laurent ^b,d,f   Rossignol, Julien ^a,g   Dunbar, Gary L ^a,f  

^a CENTRAL MICHIGAN UNIVERSITY   (United States)

^b UNIVERSITÉ DE NANTES   (France)

^c INSERM   (France)

^d Universite de Nantes   (France)

^e Field Neurosciences Institute   (United States)

^f HÔTEL DIEU   (France)

^g Central Michigan University College of Medicine   (United States)

Author keywords

3 Nitropropionic acid; Adenovirus; Huntington's disease; iPSC; Stem cell; Transplantation

Indexed keywords

3 NITROPROPIONIC ACID;

ADENOVIRUS; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION; HISTOLOGY; HUNTINGTON CHOREA; IMMUNOCYTOCHEMISTRY; IMMUNOHISTOCHEMISTRY; MALE; MRNA EXPRESSION ASSAY; NONHUMAN; NUCLEAR REPROGRAMMING; PLURIPOTENT STEM CELL; RAT; REAL TIME POLYMERASE CHAIN REACTION; RNA ISOLATION; STEM CELL TRANSPLANTATION;

3-NITROPROPIONIC ACID; ADENOVIRUS; HUNTINGTON'S DISEASE; IPSC; STEM CELL; TRANSPLANTATION;

ADENOVIRIDAE; ANIMALS; BEHAVIOR, ANIMAL; CONVULSANTS; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; FEMALE; HUNTINGTON DISEASE; INDUCED PLURIPOTENT STEM CELLS; MALE; NITRO COMPOUNDS; PROPIONATES; RATS; RATS, SPRAGUE-DAWLEY; STEM CELL TRANSPLANTATION; TRANSDUCTION, GENETIC;

EID: 84899672278     PISSN: 21576564     EISSN: 21576580     Source Type: Journal    
DOI: 10.5966/sctm.2013-0151     Document Type: Article

References (43)

1. The Huntington's Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 1993;72:971-983.
2. Estrada Sánchez AM, Mejía-Toiber J, Massieu L. Excitotoxic neuronal death and the pathogenesis of Huntington's disease. ArchMedRes 2008;39:265-276.
3. Southwell AL, Ko J, Patterson PH. Intrabody gene therapy ameliorates motor, cognitive, and neuropathological symptoms in multiple mouse models of Huntington's disease. J Neurosci 2009;29:13589-13602.
4. Bachoud-Lévi A-C. Neural grafts in Huntington's disease: Viability after 10 years. Lancet Neurol 2009;8:979-981.
5. Cicchetti F, Saporta S, HauserRAet al. Neural transplants in patients with Huntington's disease undergo disease-like neuronal degeneration. Proc Natl Acad Sci USA 2009;106:12483-12488.
6. Reuter I, Tai YF, Pavese N et al. Long-term clinical and positron emission tomography outcome of fetal striatal transplantation in Huntington's disease. J Neurol Neurosurg Psychiatry 2008;79:948-951.
7. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006;126:663-676.
8. Yamanaka S, BlauHM. Nuclear reprogramming to a pluripotent state by three approaches. Nature 2010;465:704-712.
9. WernigM, Meissner A, Foreman R et al. In vitroreprogrammingof fibroblasts intoa pluripotent ES-cell-like state. Nature 2007;448:318-324.
10. Okita K, Ichisaka T, Yamanaka S. Generation of germline-competent induced pluripotent stem cells. Nature 2007;448:313-317.
11. Peng J, Zeng X. The role of induced pluripotent stem cells inregenerativemedicine: Neurodegenerativediseases. StemCell ResTher2011;2:32.
12. Fink KD, Rossignol J, Lu M et al. Survival and differentiation of adenovirus-generated induced pluripotent stem cells transplanted into the rat striatum. Cell Transplant 2013 [Epub ahead of print].
13. Túnez I, Tasset I, Pérez-De La Cruz V et al. 3-Nitropropionic acid as a tool to study the mechanisms involved in Huntington's disease: Past, present and future. Molecules 2010;15:878-916.
14. Shear DA, Haik KL, Dunbar GL. Creatine reduces 3-nitropropionic-acid-induced cognitive and motor abnormalities in rats. Neuroreport 2000;11:1833-1837.
15. Rossignol J, Boyer C, Lévèque X et al. Mesenchymal stem cell transplantation and DMEM administration in a 3NP rat model of Huntington's disease:Morphological and behavioral outcomes. Behav Brain Res 2011;217:369-378.
16. El Massioui N, Ouary S, Chéruel F et al. Perseverative behavior underlying attentional set-shifting deficits in rats chronically treated with the neurotoxin 3-nitropropionic acid. Exp Neurol 2001;172:172-181.
17. Beal MF. Huntington's disease, energy, and excitotoxicity. Neurobiol Aging 1994;15: 275-276.
18. Brouillet E, Guyot MC, Mittoux V et al. Partial inhibition of brain succinate dehydrogenase by 3-nitropropionic acid is sufficient to initiate striatal degeneration in rat. J Neurochem 1998;70:794-805.
19. Rossignol J, Fink K, Davis K et al. Transplants of adult mesenchymal and neural stem cells provide neuroprotection and behavioral sparing in a transgenic rat model of Huntington's disease. STEM CELLS 2014;32:500-509.
20. Rossignol J, Boyer C, Thinard R et al. Mesenchymal stem cells induce a weak immune response in the rat striatum after allo or xenotransplantation. J Cell Mol Med 2009;13:2547-2558.
21. Paxinos G, Watson C. The Rat Brain in Stereotaxic Coordinates 4th ed. London, U.K.: Elsevier, 1998.
22. West MJ, Slomianka L, Gundersen HJ. Unbiased stereological estimation of the total number of neurons in the subdivisions of the rat hippocampus using the optical fractionator. Anat Rec 1991;231:482-497.
23. Armstrong RJ, Watts C, Svendsen CN et al. Survival, neuronal differentiation, and fiber outgrowth of propagated human neural precursor grafts in an animal model of Huntington's disease. Cell Transplant 2000;9:55-64.
24. Bernreuther C, Dihné M, Johann V et al. Neural cell adhesion molecule L1-transfected embryonic stem cells promote functional recovery after excitotoxic lesion of the mouse striatum. J Neurosci 2006;26:11532-11539.
25. Dunnett SB, Carter RJ, Watts C et al. Striatal transplantation in a transgenicmousemodel of Huntington'sdisease. ExpNeurol1998;154:31-40.
26. McBride JL, Behrstock SP, Chen E-Y et al. Human neural stem cell transplants improve motor function in a rat model of Huntington's disease. J Comp Neurol 2004;475:211-219.
27. Ryu JK, Kim J, Cho SJ et al. Proactive transplantation of human neural stem cells prevents degeneration of striatal neurons in a rat model of Huntington disease. Neurobiol Dis 2004;16: 68-77.
28. Song J, Lee S-T, Kang W et al. Human embryonic stem cell-derived neural precursor transplants attenuate apomorphineinduced rotational behavior in rats with unilateral quinolinic acid lesions. Neurosci Lett 2007;423:58-61.
29. Lee S-T, Chu K, Park J-E et al. Intravenous administration ofhumanneural stem cells induces functional recovery in Huntington's disease rat model. Neurosci Res 2005;52:243-249.
30. Pineda JR, Rubio N, Akerud P et al. Neuroprotection by GDNF-secreting stem cells in a Huntington's disease model: Optical neuroimage tracking of brain-grafted cells. Gene Ther 2007;14:118-128.
31. Roberts TJ, Price J, Williams SCR et al. Preservation of striatal tissue and behavioral function after neural stem cell transplantation in a rat model of Huntington's disease. Neuroscience 2006;139:1187-1199.
32. Crittenden JR, Graybiel AM. Basal Ganglia disorders associated with imbalances in the striatal striosome and matrix compartments. Front Neuroanat 2011;5:59.
33. Johann V, Schiefer J, Sass C et al. Time of transplantation and cell preparation determine neural stem cell survival in a mouse model of Huntington's disease. Exp Brain Res 2007;177: 458-470.
34. Nadeau S, Rivest S. Regulation of the gene encoding tumor necrosis factor alpha (TNF-alpha) in the rat brain and pituitary in response in differentmodels of systemic immune challenge. J Neuropathol Exp Neurol 1999;58:61-77.
35. Shear DA, Dong J, Haik-Creguer KL et al. Chronic administration of quinolinic acid in the rat striatum causes spatial learning deficits in a radial arm water maze task. Exp Neurol 1998;150:305-311.
36. Dey ND, Bombard MC, Roland BP et al. Genetically engineered mesenchymal stem cells reduce behavioral deficits in the YAC 128 mouse model of Huntington's disease. Behav Brain Res 2010;214:193-200.
37. Dunbar GL, Sandstrom MI, Rossignol J et al. Neurotrophic enhancers as therapy for behavioral deficits in rodent models of Huntington's disease: Use of gangliosides, substituted pyrimidines, and mesenchymal stem cells. Behav Cogn Neurosci Rev 2006;5:63-79.
38. Lescaudron L, Unni D, Dunbar GL. Autologous adult bone marrowstem cell transplantation in an animal modelof Huntington's disease: Behavioral and morphological outcomes. Int J Neurosci 2003;113:945-956.
39. Ma L, Hu B, Liu Y et al. Human embryonic stem cell-derived GABA neurons correct locomotion deficits in quinolinic acid-lesioned mice. Cell Stem Cell 2012;10:455-464.
40. Toivonen S, Ojala M, Hyysalo A et al. Comparative analysis of targeted differentiation of human induced pluripotent stem cells (hiPSCs) and human embryonic stem cells reveals variability associated with incomplete transgene silencing in retrovirally derived hiPSC lines. STEM CELLS TRANSL MED 2013;2:83-93.
41. NakagawaM, Koyanagi M, Tanabe K et al. Generation of induced pluripotent stem cells without Myc from mouse and human fibroblasts. Nat Biotechnol 2008;26:101-106.
42. Li H-Y, Chien Y, Chen Y-J et al. Reprogramming induced pluripotent stem cells in the absence of c-Myc for differentiation into hepatocyte-like cells. Biomaterials 2011;32: 5994-6005.
43. Fang I-M, Yang C-M, Yang C-H et al. Transplantation of induced pluripotent stem cells without C-Myc attenuates retinal ischemia and reperfusion injury in rats. Exp Eye Res 2013;113:49-59.